Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Download All
Learn from experts about the monitoring and management recommendations for corneal events associated with antibody–drug conjugates used to treat patients with cancer. Review expert insights in a clinical commentary along with downloadable slides, and on-demand webcast adapted from a live CCO webinar.
Asim V. Farooq, MD
Joann Kang, MD

PDF Resource

Download this summary resource for a quick guide on identifying and managing ocular toxicities associated with FDA-approved antibody-drug conjugates for patients with cancer.

Asim V. Farooq, MD Joann Kang, MD Released: January 31, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings